

Index

- activation markers, expression of 66
- acute contact dermatitis 205
- adjuvant arthritis, model of 65
- airway hyperresponsiveness 188
- allergen, desensitisation 43
- allergic IgE Th2-cell atopic 173
- alloantigen 221, 223–228
- allograft rejection 225
- allorecognition 224
- alloresponse, suppression of 64
- animal models for diabetes 26–31
- anti-CD3 97, 120, 227
- anti-CD3 monoclonal antibody 120
- anti-CD3 therapy 227
- anti-CD4 monoclonal antibody-therapy 228
- anti-CD25 monoclonal antibody 212
- anti-CD25 therapy 228
- antigen specificity 20–22
- antigen-presenting cells (APCs) 135, 141, 225
- antigen-presenting-cell (APC) function 225
- anti-TNF- α mAb, treatment with 155
- arthritis models, experimental 157
- atopic dermatitis 205
- atopic disease 174
- autoimmune disease 3–12
- autoimmune haemolytic anaemia 43
- autoimmunity, mouse model 137
- autologous aPCs 141
- Avonex 146
- bacterial colonization of the skin 208
- basiliximab 212
- Betaferon 146
- Betaseron 146
- bone marrow transplantation 222
- BXL-219 99
- bystander suppression 23, 25
- cadherin 211
- calcineurin inhibitors 227, 228
- candidate markers, for identification of T_R cells 223
- cardiac allograft 222, 228
- CCL1 207
- CD4⁺ T cells, depleted of CD25⁺ cells 209
- CD4⁺CD25⁺ regulatory T cells and multiple sclerosis 133
- CD4⁺CD25⁺ subset of T_R cells, features 137–141
- CD4⁺CD25⁺ T cells from synovial fluid, phenotype of 159
- CD4⁺CD25⁺T cells in synovial fluid 159
- CD4⁺CD25⁻ T cells from synovial fluid, phenotype of 159
- CD4⁺CD25⁺ T_R cells, experimental arthritis models 157

- CD4⁺CD25⁺ T_R cells, expanding *in vivo* 164
CD4⁺CD25⁺ T_R cells, expanding or generating
in vitro 163
CD25 7–12, 46, 222–224
CD25⁺CD4⁺ T_R cells 78
αεβ-(CD103) 207
CD122 223
CD134 (OX₄₀) 65
chemokine CCR8 206
chemokine receptor 100
chronic inflammation 22
clinically definite MS (CDMS) 134
clones, T_R cell 52
colitis 47
Copaxone 140, 141, 146
co-stimulation, APCs 144
CTLA-4 46, 226
cutaneous B16 melanoma 205
cutaneous infection 205
cutaneous lymphocyte antigen (CLA) 206
CXCL10 100
cyclosporine 227, 228
CYP24 99
- dacluzimab 212
delayed-type hypersensitivity reaction 205
dendritic cell (DC) 42, 79, 101
dermatitis 205
dexamethasone 211, 226, 229
diabetes, animal models 26–31
diabetes, autoimmune murine 52
1α,25-Dihydroxyvitamin D₃ 211
dinitrochlorobenzene (DNCB) 210
disease models, *in vivo* and *in vitro* 46
disease-modifying antirheumatic drugs
(DMARDs) 155
- E-cadherin 211
Epstein-Barr virus (EBV) 42
E-selectin 208
experimental allergic encephalomyelitis
52
- experimental autoimmune encephalomyelitis
(EAE), animal model 135
- fixed drug eruptions 205
Foxp3 7, 9, 11, 12, 23, 46, 95, 99, 207, 223
Foxp3 gene 207
- gastritis, autoimmune 51
glatiramer acetate (Copaxone) 140, 141, 146
glucocorticoid-induced tumour necrosis factor
receptor (GITR) 46, 223
glucocorticoid-induced tumour necrosis factor
(TNF) receptor family-related gene (GITR)
223
goodpasture's disease 43
graft rejection, control *via* T_R cells 222
graft-*versus*-host disease 212, 226
graft-*versus*-host disease, acute 222
- HA transgenic mouse 137
haptens 210
Helicobacter hepaticus 5 1, 83
hepatitis C virus 43
Hodgkin's lymphoma 43
homeostasis 19, 21, 24, 25, 54, 70, 137
homeostasis, organismal 19, 21
homeostasis regulation in TR function 24, 25
homeostatic expansion 54
homeostatic imbalance 25
homing of T_R cells 227
house dust mite 205
hTLV-1 134
- IL-10 39, 52, 84, 173, 181, 206
IL-10, produced by B-cells 52
IL-10, properties 39
IL-10 immunotherapy 173
IL-12 135, 136
IL-21 25
- immune dysregulation, polyendocrinopathy,
enteropathy, X-linked (IPEX) syndrome 207
immune homeostasis 21

- immune tolerance 120
Immune Tolerance Network 224
immunopathology 22, 25
immunoregulation, mechanisms by T_R cells
225, 226
immunosuppressive drugs, impact on T_R cells
227–229
immunotherapy 173, 188
induced TR 20
inducible co-stimulator (ICOS) 96
infectious tolerance 23, 25
inflammatory bowel disease (IBD) 82
inflammatory response, suppression of 71
influenza hemagglutinin (HA) peptide 137
integrin expression 53, 207
integrin $\alpha_4\beta_7$ 207
iT_R 23
- juvenile idiopathic arthritis (JIA) 159
- LEA29Y 228
Leishmania 47, 209
leishmaniasis 209
lymphoid organs, T cell distribution over 66
- macrophage 155
medication, influence 162
mouse model of autoimmunity 137
multiple sclerosis 133, 134
Mycobacterium tuberculosis 209
mycophenolate mofetil (MMF) 211, 228
myelin basic protein (MBP) 135
myelin oligodendrocyte glycoprotein (MOG)
135, 141
myeloid DCs 101
- natural killer T (NKT) cells 116, 222
natural T_R cells 20, 46
nematode 43
nickel 206
NOD2 82
non-autoimmune mice 25
non-obese diabetic (NOD) 25, 95, 111, 137
non-obese diabetic (NOD) mouse 25, 137
“non-self” antigen 21
non-steroidal anti-inflammatory drugs (NSAIDs)
155
nuclear factor κ B (NF- κ B) 83, 101
- 1,25(OH)₂D₃ 98
oligoclonal bands 134
organ transplantation 222
organ-specific autoimmune diseases, suppression
of 63
- PBMCs 136, 138, 139, 141
PD-1/PD-L1
pathway 226
peripheral lymphocyte 24, 25
peripheral lymphocyte homeostasis 24
phototherapy 212
plasmacytoid DCs 101
PLP-reactive T cells 135
primary progressive MS (PPMS) 133, 134
proteolipid protein (PLP) 135
psoriasis 205
- Rebif 146
recombinant interferon B-1a 146
recombinant interferon B-1b 146
regulatory T cells, activation of 64
regulatory T cells, migration of 66
regulatory T cells, origin of 64
regulatory T cells, phenotype of 65
regulatory T cells, subpopulations of 64
regulatory/suppressor T cells 95
relapsing-remitting MS (RRMS) 133, 134, 146,
147
rheumatoid arthritis (RA) 153, 155
rheumatoid arthritis (RA), mechanisms of
disease 153
rheumatoid arthritis (RA), therapeutic strategies
155
rISET initiative 224

- scurfin 223
- secondary progressive MS (SPMS) 134, 147
- selectin 208
- self-antigen 21, 63, 137, 140
- self-antigen, recognition of 63
- self-antigen-MHC complexes 140
- self reactivity 21
- self-tolerance 4, 6, 10–12
- skin 205, 208, 224
- skin-graft rejection 224
- suppression, cytokine independent 47
- synovial fluid (SF) 158, 159

- tacrolimus 212, 227, 228
- TCR transgenic mouse 137
- telomeres 53
- TGF- β 41, 112, 225, 226
- Th3 cells 41, 206
- Th3 subset 137
- therapeutic applications of T_R cells 226
- therapeutic potential of T_R cells 25
- therapy, shortcomings 164
- thymic maturation process 20
- thymic patterns of self- antigen expression 24

- thymic selection 20–22
- TNF- α 146
- toll-like receptor (TLR) 78, 100
- T_R 1 cells 41, 137, 206
- T_R cells, definition of 19
- T_R development 23
- T_R function in type 1 diabetes 26–31
- trafficking of T_R cells 227
- transforming growth factor (TGF)- β 41, 112, 225, 226
- tuberculin purified protein derivative (PPD) 209
- tumour vaccine 205
- type 1 diabetes (T1D) 24–31, 95

- ultraviolet light 205
- unresponsiveness, immunological 70

- varicella zoster virus 134
- VDR ligands 98
- vitamin D derivative 205
- vitamin D receptor (VDR) 98
- vitamin D₃ 98, 226, 228, 229